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Regression of follicular  
lymphoma with Devil’s Claw: 
coincidence or causation?
K.S. Wilson m d  (edin)
Devil’s Claw. The timing of the response suggests 
a positive effect. Further investigation is warranted, 
preferably with a c o x -2 inhibitor of known purity.
KEY WORDS
Low-grade lymphoma, alternative therapy, c o x -2 
inhibition
1.  INTRODUCTION
Several clinical trials have investigated the role of 
“immediate” as opposed to “delayed” chemotherapy 
in asymptomatic patients with advanced low-grade 
lymphoma 1–6. Treatment intensity has varied from 
mild (oral chlorambucil) to multi-agent aggressive 
(ProMACE–CytaBOM). Immediate chemotherapy 
regimens have consistently failed to show a survival 
advantage over delayed treatment. Accordingly, pa-
tients are recommended to follow a surveillance 
program to monitor for symptoms and signs of pro-
gression that would warrant treatment intervention. 
More recently, new biologic treatment options, nota-
bly rituximab and tositumomab, which are effective 
both in untreated and in previously treated patients, 
have emerged, but remain untested in phase iii trials 
in asymptomatic patients 7–9.
In cancer patient populations, use of comple-
mentary and alternative therapies is widespread 10, 
reflecting the current state of the art with respect to 
conventional systemic therapies—that is, the failure 
of those therapies to cure most of the common meta-
static epithelial malignancies and their well-known 
short- and long-term toxicity profiles. Even the “sen-
sitive” cancers—most low-grade and a substantial 
proportion of intermediate-grade B-cell malignancies, 
most T-cell malignancies, and most adult leukemia—
are often fundamentally incurable. In a study of 26 
surveys from 13 countries, the use of complementary 
and alternative therapies ranged from 7% to 64%. In 
adult patients, the average prevalence of such use was 
31% 11. Here, I report two patients who used Devil’s 
Claw supplements and who had objective tumour 
regressions confirmed on computed tomography (c t ) 
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Background
Cancer patients frequently use alternative therapies. 
Two follicular lymphoma patients who had objective 
tumour regression after taking Devil’s Claw without 
cytotoxic therapy are reported here.
Methods and Results
Patient 1 presented with coexistent immunoglobu-
lin G plasma cell dyscrasia and stage iiia lymphoma 
(nodes 5 cm in diameter). Computed tomography scan 
10 months later showed partial regression. On enqui-
ry, it was learned that the patient was taking Devil’s 
Claw and Essiac (Essiac Products Services, Pompano 
Beach, FL, U.S.A.). This patient later developed overt 
myeloma, at which time he stopped the herbal supple-
ments and underwent high-dose chemotherapy and 
stem cell transplantation, since which no lymphoma 
progression has occurred. Patient 2 presented with 
stage iiia lymphoma (nodes 2.5 cm in diameter). He 
learned of patient 1 through our lymphoma patient 
support group and started Devil’s Claw. Computed 
tomography scan 11 months later showed decreased 
adenopathy and splenomegaly, which has been sus-
tained for 4 years.
Discussion and Conclusions
Devil’s Claw tuberous root has anti-inflammatory 
properties, probably through suppression of cycloox-
ygenase 2 (c o x -2) and inducible nitric oxide synthase 
expression. There are no prior reports of anticancer 
activity. Inhibition of c o x -2 has a role in colon cancer 
prevention, has been implicated in lymphomagenesis, 
and is associated both with lymphoma stage and 
with response to treatment. However, spontaneous 
regression in lymphoma has been reported in 16% of 
patients in one series, of whom none were on herbal 
medications or c o x -2 inhibitors. The key issue in 
both these patients is whether disease regression was 
“spontaneous” or causally related to therapy with 
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scanning. Whether these regressions were causally 
related to the intervention or were coincidental is 
uncertain, but the timing of the intervention points 
to a treatment effect.
2.  PATIENTS AND METHODS
From a personal malignant lymphoma practice 
during 28 years at the BC Cancer Agency, I report 
two patients with low-grade lymphoma manifest-
ing disease regression after the use of Devil’s 
Claw supplements.
Patient 1 presented at age 57 in January 2000 
with a left lower cervical neck lymph node mass 
5 cm in diameter. Incisional biopsy revealed follicular 
lymphoma, grade 2. He was asymptomatic. Physical 
examination was otherwise normal. An abdominal 
c t  scan showed a left para-aortic lymph node mass 
5 cm in diameter. Bone marrow examination showed 
abnormal plasma-cell infiltrate (5% of cellularity) 
with kappa monoclonality. Relevant investigations 
included serum M protein (10.4 g/L); serum immu-
noglobulin G (IgG) kappa, IgA and IgM (normal); 
albumin (40 g/L); calcium (2.25 mmol/L); creatinine 
(87 μmol/L); β2-microglobulin (1.1 mg/L); and skel-
etal survey (negative).
Because this patient was asymptomatic, observa-
tion was recommended, with review in 3 months. Of 
his own volition, he started taking supplements of 
Devil’s Claw extract 500 mg daily and Essiac  (Essiac 
Products Services, Pompano Beach, FL, U.S.A.) from 
a health food store. When assessed in July 2000, the 
left neck mass was no longer palpable. Follow-up c t  
scan in November 2000 showed a marked reduction 
in the size of the retroperitoneal nodes (Figure 1). He 
developed overt myeloma in August 2001, at which 
time he stopped the herbal supplements and received 
dexamethasone, followed by high-dose melphalan, 
cyclophosphamide, and autologous peripheral blood 
stem-cell rescue. His myeloma responded, but there 
has since been evidence of paraprotein progression. 
No clinical progression of his cervical adenopathy has 
been observed through September 2008, probably as a 
result of the high-dose chemotherapy. He has not had 
a further c t  scan because of contrast risk in patients 
with myeloma proteins.
Patient 2 presented in November 2003 at age 69 
with transient abdominal pain, which led to ultra-
sound examination. Imaging showed splenomegaly 
and retroperitoneal adenopathy. There were no con-
stitutional symptoms. On physical examination, he 
had multiple enlarged superficial lymph nodes (neck, 
axillae, and inguinal regions) up to 2.5 cm in diam-
eter. A c t scan confirmed widespread adenopathy 
and splenomegaly. There was also a calcified nodule 
in the spleen. Inguinal lymph node biopsy showed 
follicular lymphoma grade 1. With clinical stage iiia 
disease, observation was recommended. He learned 
of patient 1 through our lymphoma patient support 
group and started Devil’s Claw supplements 500 mg 
daily. Follow-up abdominal c t 11 months later showed 
“significant interval improvement” in adenopathy 
f i g u r e  1   Patient 1: abdominal computed tomography scans showing regression of retroperitoneal adenopathy.FOLLICULAR LYMPHOMA: ALTERNATIVE THERAPY
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and splenomegaly, which has been sustained through 
April 2007 (Figure 2). In September 2008, only 1 
cervical lymph node (1 cm in diameter) was palpable. 
He continues to take Devil’s Claw supplements.
3.  DISCUSSION AND SUMMARY
Devil’s Claw (Harpagophytum procumbens 12) tuberous 
root contains harpagoside and β-sitosterol. It has 
anti-inflammatory and analgesic properties, probably 
through suppression of cyclooxygenase-2 (c o x -2) 
and inducible nitric oxide synthase expression 13. 
There is evidence supporting its use in osteoarthritis 
and low back pain 14, but none indicating anticancer 
activity. Inhibition of c o x -2 has an accepted role in 
cancer prevention 15, has been implicated in lym-
phomagenesis 16, and is associated both with stage 
of lymphoma and with response to treatment 17. Ex-
pression of c o x -2 has been reported in myeloma 18, 
but use of Devil’s Claw in patient 1 did not prevent 
myeloma evolution.
Patient 1 also took Essiac 19,20, a herbal tea with 
several constituents, including burdock root, Indian 
rhubarb root, sheep sorrel, and slippery elm. The only 
positive anticancer effect observed in preclinical test-
ing was in prostate and ovarian cancer cell lines; all 
leukemia, lymphoma, sarcoma, and solid-tumour tests 
were negative 19,21. No formal phase i or ii clinical 
trials of Essiac have been conducted. A retrospective 
chart review of 86 Canadian patients who took Essiac 
could not attribute changes in cancer status to Essiac. 
Accordingly, the lymphoma regression in patient 1 is 
likely not attributable to Essiac.
The key issue in both these patients is whether 
the disease regression was “spontaneous” or caus-
ally related to Devil’s Claw therapy. Neither pa-
tient was taking any other herbal or prescription 
medications besides those described. In low-grade 
lymphoma, apparently-spontaneous regression has 
been reported in 7 of 44 patients (16%) on observa-
tion only 22 and has lasted from 6 to 60+ months 
(median: 14 months). In 2 of those patients, a viral 
illness occurred before the observed lymphoma re-
gression, but no patients were known to be on herbal 
medications or c o x  inhibitors. Altogether, a total 
of 9 patients experienced spontaneous regression, 
including 2 patients with aggressive lymphomas, for 
a total incidence of 20%. In another series, sponta-
neous regressions were more frequent in follicular 
than in diffuse lymphoma (13% vs. 3%, chi-square 
p = 0.02), and 7 of 20 spontaneous remissions lasted 
more than 1 year 23.
Potential explanations for spontaneous regres-
sions have been reviewed 24. Infections may stimulate 
immune surveillance by cellular and antibody-mediated 
mechanisms. The role of immune surveillance is 
exemplified by the development of lymphoma, 
mostly higher grade, in organ transplant patients 
receiving immunosuppressive therapy. However, 
most lymphoma patients exhibiting spontaneous 
regression do not have a precipitating factor. In the 
cases reported here, the only “intervention” or 
“event” was the use of Devil’s Claw supplements. 
The chance of observing spontaneous regression in 
2 consecutive lymphoma patients can be estimated 
at approximately 2%.
f i g u r e  2   Patient 2: computed tomography scans showing decreased adenopathy and splenomegaly.WILSON
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To evaluate the anticancer effects of Devil’s 
Claw, further laboratory and clinical testing would 
be necessary. However, Devil’s Claw has not been 
evaluated by Health Canada or the U.S. Food and 
Drug Administration for safety or purity. Furthermore, 
no regulated manufacturing standards are currently 
in place for complementary medicines. Indeed, some 
herbal and health supplements have been found to 
be contaminated with toxic metals or other drugs. 
Considering the role of c o x -2 inhibitors and the re-
lationship between the components of Devil’s Claw 
and c o x -2, it may be more prudent to investigate an 
established c o x -2 inhibitor in low-grade lymphoma, 
given that the manufacture, chemical constituents, and 
toxicity profiles of those agents are well known.
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